J&J Experimental Diabetes Drug Helps High-Risk Patients

Johnson & Johnson’s experimental diabetes drug lowered blood sugar for the most vulnerable patients in two studies, including older people who struggle to control the condition and those at high risk of heart disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.